Evaluation of a CD206-Targeted Peptide for PET Imaging of Macrophages in Syngeneic Mouse Models of Cancer.

Tumor-associated macrophages (TAMs) are large phagocytic cells that play numerous roles in cancer biology and are an important component of the relationship between immune system response and tumor progression. The peptide, RP832c, targets the Mannose Receptor (CD206) expressed on M2-like macrophages and is cross-reactive to both human and murine CD206. Additionally, it exhibits therapeutic properties through its ability to shift the population of TAMs from an M2-like (protumor) toward an M1-like phenotype (antitumor) and has demonstrated promise in inhibiting tumor resistance in PD-L1 unresponsive melanoma murine models. In addition, it has shown inhibition in bleomycin-induced pulmonary fibrosis through interactions with CD206 macrophages.1,2 Our work aims to develop a novel CD206 positron emission tomography (PET) imaging probe based on RP832c (Kd = 5.64 μM) as a direct, noninvasive method for the assessment of TAMs in mouse models of cancer. We adapted RP832c to incorporate the chelator DOTA to allow for radiolabeling with the PET isotope 68Ga (t1/2 = 68 min; ß+ = 89%). In vitro stability studies were conducted in mouse serum up to 3 h. The in vitro binding characteristics of [68Ga]RP832c to CD206 were determined by a protein plate binding assay and Surface Plasmon Resonance (SPR). PET imaging and biodistribution studies were conducted in syngeneic tumor models. Stability studies in mouse serum demonstrated that 68Ga remained complexed up to 3 h (less than 1% free 68Ga). Binding affinity studies demonstrated high binding of [68Ga]RP832c to mouse CD206 protein and that the binding of the tracer was able to be blocked significantly when incubated with a blocking solution of native RP832c. PET imaging and biodistribution studies in syngeneic tumor models demonstrated uptake in tumor and CD206 expressing organs of [68Ga]RP832c. A significant correlation was found between the percentage of CD206 present in each tumor imaged with [68Ga]RP832c and PET imaging mean standardized uptake values in a CT26 mouse model of cancer. The data shows that [68Ga]RP832c represents a promising candidate for macrophage imaging in cancer and other diseases.

[1]  Zhentao Yang,et al.  Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. , 2021, Cancer cell.

[2]  S. Lapi,et al.  Positron Emission Tomography Imaging of Macrophages in Cancer , 2021, Cancers.

[3]  P. Delvenne,et al.  Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy , 2021, Journal for ImmunoTherapy of Cancer.

[4]  E. Löyttyniemi,et al.  Evaluation of [18F]F-DPA as a target for TSPO in head and neck cancer under normal conditions and after radiotherapy , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  Xikun Zhou,et al.  Tumor-Associated Macrophages: Recent Insights and Therapies , 2020, Frontiers in Oncology.

[6]  Jason B. White,et al.  Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses , 2020, Science Translational Medicine.

[7]  N. Inui,et al.  Macrophage Mannose Receptor CD206 Predicts Prognosis in Community-acquired Pneumonia , 2019, Scientific Reports.

[8]  S. Barry,et al.  Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery , 2019, Journal of Immunotherapy for Cancer.

[9]  Yibing Chen,et al.  Tumor-associated macrophages: an accomplice in solid tumor progression , 2019, Journal of Biomedical Science.

[10]  Huiyin Lan,et al.  Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications , 2019, Journal of Hematology & Oncology.

[11]  N. Devoogdt,et al.  Clinical Translation of [68Ga]Ga-NOTA-anti-MMR-sdAb for PET/CT Imaging of Protumorigenic Macrophages , 2019, Molecular Imaging and Biology.

[12]  X. Shao,et al.  Tracking Macrophage Infiltration in a Mouse Model of Pancreatic Cancer with the Positron Emission Tomography Tracer [11C]PBR28. , 2018, The Journal of surgical research.

[13]  N. Inui,et al.  Macrophage mannose receptor, CD206, predict prognosis in patients with pulmonary tuberculosis , 2018, Scientific Reports.

[14]  Yiping Yang,et al.  Tumor-associated macrophages: implications in cancer immunotherapy. , 2017, Immunotherapy.

[15]  Hongjuan Zhao,et al.  RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials , 2017, Expert opinion on investigational drugs.

[16]  M. Mino‐Kenudson,et al.  Type I collagen–targeted PET probe for pulmonary fibrosis detection and staging in preclinical models , 2017, Science Translational Medicine.

[17]  W. Breeman,et al.  Radiolabeling of DOTA-like conjugated peptides with generator-produced 68Ga and using NaCl-based cationic elution method , 2016, Nature Protocols.

[18]  Murugesan V. S. Rajaram,et al.  The inextricable axis of targeted diagnostic imaging and therapy: An immunological natural history approach. , 2016, Nuclear medicine and biology.

[19]  Paul Kinahan,et al.  Positron Emission Tomography: Current Challenges and Opportunities for Technological Advances in Clinical and Preclinical Imaging Systems. , 2015, Annual review of biomedical engineering.

[20]  Jeffrey W Pollard,et al.  Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.

[21]  Thomas A. Wynn,et al.  Macrophage biology in development, homeostasis and disease , 2013, Nature.

[22]  Jeffrey W. Pollard,et al.  Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.

[23]  B. Monsarrat,et al.  A New Generation of Melan-A/MART-1 Peptides That Fulfill Both Increased Immunogenicity and High Resistance to Biodegradation: Implication for Molecular Anti-Melanoma Immunotherapy1 , 2001, The Journal of Immunology.